文献速递乳腺癌支持与姑息治疗

早期乳腺癌全身治疗患者心脏影像实践中的风险-影像错配:基于人群的队列研究

Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study.
PubMed 文献 · J Clin Oncol · 2018-05-23

该研究在加拿大安大略省纳入2007至2012年接受化疗的18444例早期乳腺癌女性,评估化疗前心脏影像实践与心衰风险的关系。结果显示基线心脏影像主要由化疗方案驱动而非心衰风险因素,接受蒽环类无曲妥珠单抗且有心衰风险因素者5年主要不良心脏事件发生率为4.5%,但影像检查频率低于无风险因素接受曲妥珠单抗无蒽环类者(73.3% vs 93.6%)。

要点

  • 基线心脏影像主要由化疗方案决定,而非患者心衰风险因素。
  • 含曲妥珠单抗方案患者几乎普遍接受影像,包括无额外心衰风险因素者。
  • 有心衰风险因素者接受蒽环类无曲妥珠单抗时影像频率较低但MACE发生率较高。

核心结论

  • 基线心脏影像由化疗方案驱动而非心衰风险,存在风险-影像错配,提示需重新考虑当前心脏影像实践。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入2007至2012年加拿大安大略省接受化疗的早期乳腺癌女性18444例,中位年龄55岁。
  • 评估化疗前6个月至化疗后30天内的基线心脏影像,按化疗方案和心衰风险因素分析影像比例及主要不良心脏事件累积发生率。
  • 采用逻辑回归评估预处理心脏影像的预测因素。

主要发现

  • 接受含曲妥珠单抗方案者几乎普遍接受影像,包括无额外心衰风险因素者。
  • 接受蒽环类无曲妥珠单抗者中,有心衰风险因素者影像频率高于无风险因素者(73.3% vs 62.6%,P < .001)。
  • 所有治疗方案中,有心衰风险因素者5年MACE发生率是无风险因素者的2至6倍。
  • 有心衰风险因素接受蒽环类无曲妥珠单抗者5年MACE发生率为4.5%,高于无风险因素接受曲妥珠单抗无蒽环类者的2.6%,但影像频率更低(73.3% vs 93.6%,P < .001)。
  • 逻辑回归显示基线影像变异主要与化疗相关,其次为医生层面因素,女性医生使影像 odds 加倍,患者特异性因素包括心衰风险因素贡献极小。

临床怎么用

  • 当前心脏影像实践与心衰风险不匹配,临床应考虑根据患者心衰风险而非仅化疗方案来决定基线心脏影像。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess prechemotherapy cardiac imaging practices in relation to patients' heart failure (HF) risk. METHODS: We performed a population-based retrospective cohort study of women receiving chemotherapy for early-stage breast cancer in Ontario between 2007 and 2012. We surveyed for baseline cardiac imaging 6 months before chemotherapy or within 30 days thereafter. The proportion of patients who underwent imaging and cumulative incidence of major adverse cardiac event (MACE) rates was determined based on chemotherapy regimen and HF risk factors. Logistic regression was used to assess predictors of pretreatment cardiac imaging. RESULTS: We studied 18,444 women who had been treated with chemotherapy (median age, 55 years). There was near-universal imaging of women treated with trastuzumab-containing regimens, including those without additional HF risk factors. Women who received anthracyclines without trastuzumab underwent imaging more frequently if they had additional HF risk factors (73.3% v 62.6%; P < .001). The 5-year incidence of MACE was two to six times higher in patients with HF risk factors across all treatment regimens. Patients with HF risk factors who received anthracyclines without trastuzumab had a higher 5-year incidence of MACE (4.5%) than patients without HF risk factors who received trastuzumab without anthracyclines (2.6%). However, cardiac imaging was less frequent in the former group (73.3% v 93.6%; P < .001). Logistic regression indicated that most variation in baseline imaging was related to chemotherapy, followed by physician-level factors. The odds of imaging were doubled with female physicians. Patient-specific factors, including HF risk factors, made minimal contribution to variation in imaging. CONCLUSION: Baseline cardiac imaging was driven by chemotherapy regimen rather than HF risk. This risk-imaging mismatch is an impetus to reconsider current cardiac imaging practices in patients who receive chemotherapy for breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Thavendiranathan P, Abdel-Qadir H, Fischer HD, et al. Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study. J Clin Oncol. 2018. PMID: 29791284. doi:10.1200/JCO.2018.77.9736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。